Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.

Journal: European journal of cancer (Oxford, England : 1990)
Published Date: Jan 1, 2019

Abstract

BACKGROUND: Mutation of the isocitrate dehydrogenase (IDH) gene and co-deletion on chromosome 1p/19q is becoming increasingly relevant for the evaluation of clinical outcome in glioma. Among the imaging parameters, contrast enhancement (CE) in WHO II/III glioma has been reported to indicate poor outcome in the past. We aimed at reassessing the prognostic value of CE in these tumours within the framework of molecular markers using a machine learning approach (random survival forests [RSF]) as well as conventional Cox regression modelling.

Authors

  • Bogdana Suchorska
    Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: bogdana.suchorska@med.uni-muenchen.de.
  • Ulrich Schüller
    Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany; Institute of Neuropathology, University Medical Center, Hamburg-Eppendorf, Germany; Research Institute Children's Cancer Center, Hamburg, Germany; Department of Pediatric Hematology and Oncology, University Medical Center, Hamburg-Eppendorf, Germany.
  • Annamaria Biczok
    Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Markus Lenski
    Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Nathalie L Albert
    German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Nuclear Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Armin Giese
    German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany; Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Friedrich-Wilhelm Kreth
    Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Birgit Ertl-Wagner
    Department of Radiology, Ludwig-Maximilians-University Munich, Munich, Germany.
  • Jörg-Christian Tonn
    Department of Neurosurgery, Ludwig-Maximilians-University Munich, Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Michael Ingrisch
    Department of Radiology, Ludwig-Maximilians-University Munich, Munich, Germany.

Keywords

External Resources

Popular Topics
Recent Journals